Form 4: Pacira BioSciences CFO Shawn Cross Receives Stock Options and Restricted Stock Units

Sentiment:

SEC Form 4 Filing


Pacira BioSciences' CFO, Shawn Cross, reports the acquisition of stock options and restricted stock units, indicating changes in beneficial ownership.

Summary

  • Shawn Cross, CFO of Pacira BioSciences, reported changes in beneficial ownership on November 1, 2024.
  • Cross acquired 75,000 shares of common stock through restricted stock units, which vest in four equal annual installments starting November 1, 2025.
  • Cross also acquired options to purchase 200,000 shares of common stock at an exercise price of $16.45 on November 4, 2024.
  • These options vest 25% on the first anniversary of the grant date and the remainder in equal quarterly installments over the following three years.
  • Following these transactions, Cross directly owns 75,000 shares of common stock and options for 200,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and restricted stock units is a standard practice and generally viewed favorably as it aligns management interests with shareholders. There are no immediate negative implications.

Positives

  • The granting of stock options and restricted stock units to the CFO aligns his interests with those of the shareholders.
  • The vesting schedules encourage long-term commitment from the CFO.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with shareholder value and incentivizing long-term performance.

Comparison to Industry Standards

  • Executive compensation packages, including stock options and restricted stock units, are standard practice among publicly traded biotechnology companies.
  • Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation to incentivize their executives.
  • The vesting schedules and exercise prices are generally aligned with industry norms to ensure retention and performance.

Stakeholder Impact

  • Shareholders may view the granting of stock options and restricted stock units positively as it incentivizes management to improve company performance.
  • Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

DateDescription
11/01/2024Date of transaction for restricted stock units acquisition.
11/01/2025First vesting date for restricted stock units.
11/04/2024Date of transaction for stock options acquisition.
11/04/2034Expiration date for stock options.
11/05/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.